ACTRN12613000123741终止未知
Response to biologics in rheumatoid arthriits to determine the relationship between antidrug antibodies, drug concentrations and disease activity.
niversity of Otago, Christchurch0 个研究点目标入组 200 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •I.Male or female, aged >/=18 years, with Rheumatoid Arthritis as defined by the ACR Criteria (Aletaha et al. 2010) receiving or commencing any biologic therapy.
- •II.Able and willing to give written informed consent and to comply with the requirements of the study.
排除标准
- •patients with serious uncontrolled chronic concomitant disease
研究者
相似试验
招募中
不适用
rheumatoid arthritis: observation of biologics treatmentM05M06Seropositive rheumatoid arthritisOther rheumatoid arthritisDRKS00031523Deutsches Rheuma-Forschungszentrum Berlin30,000
已完成
不适用
Predicting response to biologics in rheumatoid arthritisRheumatoid arthritisACTRN12613000938707niversity of Otago, Christchurch100
已完成
不适用
Stratification of biologic therapies for rheumatoid arthritis by pathobiologyMusculoskeletal DiseasesRheumatoid arthritis, unspecifiedRheumatoid arthritisISRCTN10618686Queen Mary University of London187
招募中
不适用
Effects of therapeutic medication for rheumatoid arthritis on cachexia in patients with rheumatoid arthritis.rheumatoid arthritisJPRN-UMIN000017026Tokushima University100
已完成
不适用
Research into lower dosing of tofacitinib (Xeljanz®) when used in combination with cobicistat (Tybost®), a drug that reduces drug breakdowRheumatoid Arthritis, Psoriatic ArthritisNL-OMON26019Radboudumc30